A0A096N5H2 (A0A096N5H2_PAPAN) Papio anubis (Olive baboon)

Protein arginine N-methyltransferase 5 UniProtKBInterProSTRINGInteractive Modelling

637 aa; Sequence (Fasta) ; 10 identical sequences: Homo sapiens: O14744; Pan troglodytes: K7B5I7, K7AYQ8; Gorilla gorilla gorilla: G3R5J7; Theropithecus gelada: A0A8D2K4A5; Macaca mulatta: H9FNP7; Macaca fascicularis: G8F670; Rhinopithecus roxellana: A0A2K6NY20; Rhinopithecus bieti: A0AAJ7M715; Carlito syrichta: A0A1U7TTX7

Available Structures

65 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
PRMT5 complex bound to covalent PBM inhibitor BRD6711 Heteromer
O14744; Q9BQA1;
13-637
100.0QN4;CL;SFG;GOL;
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound Heteromer
O14744; Q9BQA1;
13-637
100MTA;UNL;GOL;
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound Heteromer
O14744; Q9BQA1;
13-637
100MTA;UNL;GOL;
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound Heteromer
O14744; Q9BQA1;
13-637
100MTA;UNL;GOL;
Human PRMT5:MEP50 structure with Fragment (Example 18) and MTA Bound Heteromer
O14744; Q9BQA1;
13-637
100MTA;JYX;GOL;
PRMT5/MEP50 crystal structure with MTA and phthalazinone fragment bound Heteromer
O14744; Q9BQA1;
13-637
100.0CL;NA;EDO;81X;MTA;
Crystal structure of PRMT5:MEP50 in complex with MTA Heteromer
O14744; Q9BQA1;
13-637
100MTA; 10×EDO;GOL;PEG;
Crystal Structure of the human PRMT5:MEP50 Complex Heteromer
O14744; P62805; Q9BQA1;
13-637
1000XU;
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound Heteromer
O14744; Q9BQA1;
13-637
100MTA;UNL;GOL;
PRMT5/MEP50 crystal structure with MTA and a phthalazinone inhibitor bound (compound (M)-31) Heteromer
O14744; Q9BQA1;
13-637
100MTA;85E;
PRMT5/MEP50 with compound 30 bound Heteromer
O14744; Q9BQA1;
13-637
10097L;MTA;
Human PRMT5 in complex with AZ compound 12 Heteromer
O14744; Q9BQA1;
13-637
100A1H76;MTA;SO4;
Human PRMT5 in complex with AZ compound 28 Heteromer
O14744; Q9BQA1;
13-637
100A1H73;MTA;SO4;
PRMT5/MEP50 crystal structure with sinefungin bound Heteromer
O14744; Q9BQA1;
13-637
100.0SFG;
CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJ44064146 Heteromer
O14744; Q9BQA1;
13-637
100K8H;
Crystal structure of PRMT5:MEP50 with Compound 8 and sinefungin Heteromer
O14744; Q9BQA1;
13-637
100SFG;5QJ; 16×GOL;
Human PRMT5 in complex with AZ compound 21 Heteromer
O14744; Q9BQA1;
13-637
100A1H8B;MTA;SO4;
Crystal Structure of PRMT5:MEP50 in complex with MTA and H4 peptide Heteromer
O14744; P62805; Q9BQA1;
13-637
100MTA;
Crystal structure of PRMT5:MEP50 with EPZ015666 and sinefungin Heteromer
O14744; Q9BQA1;
13-637
100SFG;3XV;GOL;
Human PRMT5 in complex with AZ compound 1 Heteromer
O14744; Q9BQA1;
13-637
100A1H8A;MTA;SO4;
Crystal structure of PRMT5:MEP50 with EPZ015866 and sinefungin Heteromer
O14744; Q9BQA1;
13-637
100SFG;4Z2;GOL;
Crystal structure of PRMT5:MEP50 with Compound 15 and sinefungin Heteromer
O14744; Q9BQA1;
13-637
100SFG;5QL;GOL;
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound Heteromer
O14744; Q9BQA1;
13-637
100MTA;UNL;GOL;CL;
Crystal structure of PRMT5:MEP50 with Compound 10 and SAM Heteromer
O14744; Q9BQA1;
13-637
100SAM;5QK;GOL;
PRMT5(M420T mutant):MEP50 complexed with inhibitor PF-06855800 Heteromer
O14744; Q9BQA1;
13-637
99.84ZR4;
PRMT5:MEP50 complexed with adenosine Heteromer
O14744; Q9BQA1;
13-637
100.0ADN;
PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 34 Heteromer
O14744; Q9BQA1;
13-637
100EDO;WFS;
Crystal structure of PRMT5:MEP50 in complex with MTA and TNG908 Heteromer
O14744; Q9BQA1;
13-637
100MTA;A1AAV;PEG;EDO;CL;
Crystal structure of PRMT5:MEP50 in complex with MTA and oxamide compound 23 Heteromer
O14744; Q9BQA1;
13-637
100MTA;A1AAT; 20×EDO;
PRMT5-MEP50 Complexed with SAM Heteromer
O14744; Q9BQA1;
13-637
10015×EDO;CL;SAM;
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound Heteromer
O14744; Q9BQA1;
13-637
100MTA;GOL;UNL;
Human PRMT5:MEP50 structure with Fragment 1 and MTA Bound Heteromer
O14744; Q9BQA1;
13-637
100PWL;MTA;PEG;EDO;
PRMT5:MEP50 complexed with inhibitor PF-06939999 Heteromer
O14744; Q9BQA1;
13-637
100.0ZR1;
PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 72 Heteromer
O14744; Q9BQA1;
13-637
100EDO;WFV;
PRMT5/MEP50 with compound 29 bound Heteromer
O14744; Q9BQA1;
13-637
10097X;MTA;
Crystal structure of PRMT5:MEP50 with Compound 9 and sinefungin Heteromer
O14744; Q9BQA1;
13-637
100SFG;5QH;GOL;
PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 4 Heteromer
O14744; Q9BQA1;
13-637
100WFM; 10×EDO;CL;PEG;
CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJ45031882 Heteromer
O14744; Q9BQA1;
13-637
100K8N;
PRMT5(M420T mutant):MEP50 complexed with inhibitor PF-06939999 Heteromer
O14744; Q9BQA1;
13-637
99.84ZR1;
PRMT5:MEP50 Complexed with Allosteric Inhibitor Compound 8 Heteromer
O14744; Q9BQA1;
13-637
100.0QKY;EDO;GOL;
PRMT5:MEP50 Complexed with Cyclonucleoside Compound 1 Heteromer
O14744; Q9BQA1;
13-637
100EDO;LB3;
Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase (PRMT5) Inhibitors Heteromer
O14744; Q9BQA1;
13-637
100CUX;DMS;EDO;
Human PRMT5:MEP50 structure with Fragment 3 and MTA Bound Heteromer
O14744; Q9BQA1;
13-637
100PWX;MTA;
PRMT5/MEP50 crystal structure with MTA and MRTX-1719 bound Heteromer
O14744; Q9BQA1;
13-637
100MTA;85K;
Crystal structure of PRMT5:MEP50 in complex with MTA and oxamide compound 1 Heteromer
O14744; Q9BQA1;
13-637
100MTA;A1AAS;EDO;CL;
HUMAN PRMT5:MEP50 COMPLEX WITH MTA and Fragment 5 Bound Heteromer
O14744; Q9BQA1;
13-637
100.0PJ0;MTA;SO4;EDO;PEG;CL;
Crystal structure of PRMT5:MEP50 in complex with MTA and oxamide compound 24 Heteromer
O14744; Q9BQA1;
13-637
100MTA;A1AAU;GOL;CL;
PRMT5/MEP50 crystal structure with MTA and an achiral, class 1, non-atropisomeric inhibitor bound Heteromer
O14744; Q9BQA1;
13-637
100NXF;MTA;
PRMT5:MEP50 complexed with inhibitor PF-06855800 Heteromer
O14744; Q9BQA1;
13-637
100.0ZR4;
PRMT5/MEP50 crystal structure with MTA and a phthalazinone inhibitor bound (Compound 9) Heteromer
O14744; Q9BQA1;
13-637
100MTA;84W;
Crystal structure of PRMT5:MEP50 in complex with MTA and oxamide compound 28 Heteromer
O14744; Q9BQA1;
13-637
100MTA;A1AAR;CL;GOL;
Structure of PRMT5:MEP50 in complex with LLY-283, a potent and selective inhibitor of PRMT5, with a… Heteromer
O14744; Q9BQA1;
13-637
100F5J;
Human PRMT5:MEP50 structure with Fragment 4 and MTA Bound Heteromer
O14744; Q9BQA1;
13-637
100.0PUI;MTA;PEG;CL;
CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJB44355437 Heteromer
O14744; Q9BQA1;
13-637
100U6K;EPE;EDO;PEG;
Crystal structure of PRMT5:MEP50 with EPZ015666 and SAM Heteromer
O14744; Q9BQA1;
13-637
100SAM;3XV;GOL;
AMG 193, a clinical stage MTA-cooperative PRMT5 inhibitor, drives anti-tumor activity preclinically… Heteromer
O14744; Q9BQA1;
13-637
100GOL;DMS;A1ATH;MTA;
PRMT5 bound to the PBM peptide from pICln Heteromer
O14744; P54105; Q9BQA1;
13-637
100SFG;ACE;
Crystal structure of PRMT5:MEP50 with EPZ015666 and SAH Heteromer
O14744; Q9BQA1;
13-637
100SAH;3XV;
Cryo-EM structure of the apo form of human PRMT5:MEP50 complex at a resolution of 3.4 angstrom Heteromer
O14744; Q9BQA1;
13-637
100.0
CryoEM structure of PRMT5 bound to covalent PBM-site inhibitor BRD-6988 Heteromer
O14744; Q9BQA1;
13-637
100.0YJG;
Cryo-EM structures and computational analysis for enhanced potency in MTA-synergic inhibition of hu… Heteromer
O14744; Q9BQA1;
13-637
100P2R;MTA;
PRMT5 bound to PBM peptide from Riok1 Heteromer
O14744; Q9BQA1; Q9BRS2;
14-637
100SFG;
PRMT5:MEP50 Complexed with Allosteric Inhibitor Compound 1a Heteromer
O14744; Q9BQA1;
14-637
100.0QL1;
Structure of the methylosome-Lsm10/11 complex Heteromer
O14744; P83369; Q61189; Q9BQA1;
14-637
100.0ADN;
Crystal structure of the PRMT5 TIM barrel domain in complex with RioK1 peptide Heteromer
O14744; Q9BRS2;
41-290
100.0

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
5fa5.3.Amonomer0.9213-637
100.00